The Antibiotic Innovation Cliff: Market Economics Have Decoupled R&D from Medical Need
Problem Definition
Antimicrobial resistance is accelerating while antibiotic R&D is collapsing. Since 2000, there have been zero new classes of systemic antibiotics approved by the FDA — we are still relying on 70-year-old drug mechanisms. The reason is not scientific; it is economic.
Antibiotics are terrible investments: they are taken for 7-14 days and then discarded, patients take them at home (no hospital margin), and competition drives prices to commodity levels. A pharmaceutical company can earn more revenue from a single cancer drug taken by 100K patients for years than from an antibiotic taken by millions of people for two weeks.
The result is that the drugs we desperately need for resistant infections are not worth making, so they are not made.
Root Causes
Antibiotics are commodities economically but critical goods medically — the value they create is social, not private
Patent incentives reward duration of use (chronic drugs) not utility (last-resort drugs)
Stewardship policies restrict antibiotic use, further reducing revenue per drug
Manufacturing has consolidated in India and China with minimal profit margins
New antibiotics take 10-15 years to develop at $1-2B cost, amortized over a declining revenue stream